PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
198 hedge funds and large institutions have $436M invested in PDL BioPharma, Inc. in 2016 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 64 increasing their positions, 60 reducing their positions, and 29 closing their positions.
10% more capital invested
Capital invested by funds: $397M → $436M (+$39.2M)
7% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 60
2% less call options, than puts
Call options by funds: $2.74M | Put options by funds: $2.8M
1% less funds holding
Funds holding: 201 → 198 (-3)
10% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$8.35M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.72M |
| 3 |
Renaissance Technologies
New York
|
+$2.88M |
| 4 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$2.35M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$6.54M |
| 2 |
GAM
Gotham Asset Management
New York
|
-$3.26M |
| 3 |
AAM
Advisors Asset Management
Monument,
Colorado
|
-$2.78M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.63M |
| 5 |
EA
Emerald Acquisition
Seattle,
Washington
|
-$2.62M |
PDLI Hedge Fund Activity: Q3 2016 in Review
198 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2016, worth a combined $436M — up 9.9% from $397M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of PDLI and 26 opened new positions — a net loss of 3 holders — while 60 trimmed existing stakes and 64 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $8.35M. The largest seller was Bank of New York Mellon, cutting an estimated $6.54M.
- 198 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2016, down from 201 in Q2 2016.
- Funds reported $436M of PDL BioPharma, Inc. stock for Q3 2016, up 9.9% quarter-over-quarter.
- 26 funds opened new PDL BioPharma, Inc. positions in Q3 2016 and 29 closed out, a net change of -3 holders.
- The largest PDL BioPharma, Inc. buyer in Q3 2016 was Armistice Capital, an estimated $8.35M added.
- The largest PDL BioPharma, Inc. seller in Q3 2016 was Bank of New York Mellon, an estimated $6.54M sold.
Based on aggregated 13F filings for Q3 2016.